Niels W C J Van De Donk

List of Publications by Year
in descending order

133 papers	9,201 citations	47006 47 h-index	43889 91 g-index
134 all docs	134 docs citations	134 times ranked	7798 citing authors

#	Article	IF	Citations
1	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood, 2022, 139, 835-844.	1.4	43
2	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica, 2022, 107, 437-445.	3.5	63
3	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 2022, 12, 32.	6.2	73
4	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of Clinical Oncology, 2022, 40, 3132-3150.	1.6	13
5	Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands. Blood Cancer Journal, 2022, 12, 41.	6.2	6
6	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia, 2022, 36, 1371-1376.	7.2	81
7	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica, 2021, 106, 1725-1732.	3.5	25
8	Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia, 2021, 35, 573-584.	7.2	67
9	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	7.2	79
10	Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma. Haematologica, 2021, 106, 2004-2008.	3.5	19
11	Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 1096.	4.1	25
12	Multiple myeloma. Lancet, The, 2021, 397, 410-427.	13.7	349
13	First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. Blood Cancer Journal, 2021, 11, 22.	6.2	5
14	Improving the identification of frail elderly newly diagnosed multiple myeloma patients. Leukemia, 2021, 35, 2715-2719.	7.2	5
15	Molecular dynamics of targeting CD38 in multiple myeloma. British Journal of Haematology, 2021, 193, 581-591.	2.5	16
16	Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. Hemato, 2021, 2, 116-130.	0.6	2
17	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	2.5	67
18	Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica, 2021, 106, 2257-2260.	3.5	22

#	Article	IF	Citations
19	Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Cancers, 2021, 13, 1571.	3.7	21
20	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
21	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. Clinical Cancer Research, 2021, 27, 3793-3803.	7.0	27
22	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances, 2021, 5, 2196-2215.	5.2	56
23	Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 302-318.	5.0	40
24	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. HemaSphere, 2021, 5, e561.	2.7	11
25	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica, 2021, 106, 2054-2065.	3.5	27
26	The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review. Cancer Imaging, 2021, 21, 36.	2.8	3
27	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. Cancers, 2021, 13, 2452.	3.7	11
28	CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematology,the, 2021, 8, e446-e461.	4.6	75
29	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	3.5	22
30	Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1963-1971.	2.3	14
31	Teclistamab, a B-cell maturation antigenâ€ˆÃ—â€ˆCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet, The, 2021, 398, 665-674.	13.7	138
32	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. Journal of Clinical Oncology, 2021, 39, 2758-2767.	1.6	25
33	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	1.6	25
34	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. Advances in Therapy, 2021, 38, 1328-1341.	2.9	2
35	Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma. Blood Advances, 2021, 5, 5128-5139.	5.2	22
36	Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. Journal of Clinical Medicine, 2021, 10, 4593.	2.4	11

#	Article	IF	Citations
37	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	4.6	46
38	Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer Journal, 2021, 11, 178.	6.2	6
39	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Science Translational Medicine, 2021, 13, eabh1962.	12.4	49
40	Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. Haematologica, 2020, 105, e80-e83.	3.5	12
41	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica, 2020, 105, 1650-1659.	3.5	19
42	Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica, 2020, 105, e302-e306.	3.5	53
43	Immunotherapy in multiple myeloma: when, where, and for who?. Current Opinion in Oncology, 2020, 32, 664-671.	2.4	5
44	Sequencing multiple myeloma therapies with and after antibody therapies. Hematology American Society of Hematology Education Program, 2020, 2020, 248-258.	2.5	10
45	Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibodyâ€“based treatment?. Hematology American Society of Hematology Education Program, 2020, 2020, 259-263.	2.5	6
46	Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. Frontiers in Oncology, 2020, 10, 1362.	2.8	45
47	Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. Frontiers in Oncology, 2020, 10, 607571.	2.8	0
48	Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies. Molecular Cancer Therapeutics, 2020, 19, 2089-2104.	4.1	3
49	Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma. HemaSphere, 2020, 4, e413.	2.7	8
50	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. Cancers, 2020, 12, 3713.	3.7	23
51	Targeted Therapy With Immunoconjugates for Multiple Myeloma. Frontiers in Immunology, 2020, 11, 1155.	4.8	38
52	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. Cells, 2020, 9, 378.	4.1	16
53	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia, 2020, 34, 1840-1852.	7.2	55
54	Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia, 2020, 34, 1964-1966.	7.2	22

#	Article	IF	Citations
55	Preclinical Activity of JNJ-7957, a Novel BCMAÃ—CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clinical Cancer Research, 2020, 26, 2203-2215.	7.0	53
56	Resistance Mechanisms towards CD38â˜'Directed Antibody Therapy in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 1195.	2.4	28
57	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica, 2020, 105, 2879-2882.	3.5	20
58	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematology,the, 2020, 7, e447-e455.	4.6	74
59	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2020, 34, 2000-2011.	7.2	109
60	A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 40-41.	1.4	46
61	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget, 2020, 11, 4076-4081.	1.8	23
62	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood, 2019, 134, 668-677.	1.4	87
63	Immunotherapy in myeloma: how far have we come?. Therapeutic Advances in Hematology, 2019, 10, 204062071882266.	2.5	47
64	Reprint of â€œImmunomodulatory effects of CD38-targeting antibodiesâ€. Immunology Letters, 2019, 205, 71-77.	2.5	14
65	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptorâ€“engineered T Cells. Clinical Cancer Research, 2019, 25, 4014-4025.	7.0	110
66	Insights on Multiple Myeloma Treatment Strategies. HemaSphere, 2019, 3, e163.	2.7	33
67	CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients. Journal of Translational Autoimmunity, 2019, 2, 100022.	4.0	16
68	CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, e100-e103.	3.5	90
69	Oral proteasome inhibitor maintenance for multiple myeloma. Lancet, The, 2019, 393, 204-205.	13.7	4
70	Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e9-e11.	0.4	19
71	Highâ€Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 279-289.	1.5	117
72	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. British Journal of Haematology, 2019, 184, 475-479.	2.5	18

#	Article	IF	Citations
73	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study. Blood, 2019, 134, 695-695.	1.4	14
74	Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study. Blood, 2019, 134, 1826-1826.	1.4	7
75	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. Blood, 2019, 134, 693-693.	1.4	18
76	Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies. Blood, 2019, 134, 3106-3106.	1.4	14
77	The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma. Blood, 2019, 134, 137-137.	1.4	10
78	The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. Blood, 2019, 134, 5549-5549.	1.4	1
79	CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Expert Review of Clinical Immunology, 2018, 14, 197-206.	3.0	30
80	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	7.2	68
81	Immunomodulatory effects of CD38-targeting antibodies. Immunology Letters, 2018, 199, 16-22.	2.5	68
82	Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica, 2018, 103, e368-e371.	3.5	43
83	Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs, 2018, 78, 19-37.	10.9	108
84	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018, 103, 197-211.	3.5	110
85	CD38 antibodies in multiple myeloma: back to the future. Blood, 2018, 131, 13-29.	1.4	329
86	Practical Considerations for Antibodies in Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 667-674.	3.8	6
87	CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Frontiers in Immunology, 2018, 9, 2134.	4.8	212
88	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematology,the, 2018, 5, e479-e492.	4.6	25
89	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	3.5	86
90	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	7.2	81

#	Article	IF	Citations
91	Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS ONE, 2018, 13, e0197349.	2.5	60
92	Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).. Journal of Clinical Oncology, 2018, 36, 8013-8013.	1.6	6
93	Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma. Oncotarget, 2018, 9, 33621-33622.	1.8	10
94	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget, 2018, 9, 34009-34021.	1.8	17
95	Could daratumumab be used to treat severe allergy?. Journal of Allergy and Clinical Immunology, 2017, 139, 1677-1678.e3.	2.9	8
96	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 2017, 102, 160-167.	3.5	49
97	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 2017, 25, 1946-1958.	8.2	197
98	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research, 2017, 23, 7498-7511.	7.0	134
99	Carfilzomib versus bortezomib: no longer an ENDEAVOR. Lancet Oncology, The, 2017, 18, 1288-1290.	10.7	9
100	Primary cardiac lymphoma with central nervous system relapse. Clinical Case Reports (discontinued), 2017, 5, 1454-1458.	0.5	9
101	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Advances, 2017, 1, 2105-2114.	5.2	155
102	A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2017, 35, TPS8055-TPS8055.	1.6	1
103	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica, 2016, 101, 616-625.	3.5	136
104	Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: longâ€term followâ€up in a single institution. European Journal of Haematology, 2016, 97, 479-488.	2.2	15
105	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 2016, 128, 2297-2306.	1.4	49
106	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs, 2016, 76, 853-867.	10.9	34
107	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood, 2016, 127, 681-695.	1.4	179
108	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood, 2016, 128, 384-394.	1.4	697

#	Article	IF	Citations
109	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962.	1.4	686
110	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, 2016, 128, 959-970.	1.4	286
111	Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. International Journal of Laboratory Hematology, 2016, 38, 110-122.	1.3	41
112	Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond. Immunological Reviews, 2016, 270, 95-112.	6.0	280
113	Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica, 2016, 101, e339-e342.	3.5	34
114	Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clinical Chemistry and Laboratory Medicine, 2016, 54, 1105-9.	2.3	65
115	A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2016, 34, TPS8072-TPS8072.	1.6	2
116	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica, 2015, 100, 263-268.	3.5	96
117	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1207-1219.	27.0	948
118	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clinical Cancer Research, 2015, 21, 2802-2810.	7.0	136
119	Monoclonal antibodies in myeloma. Clinical Advances in Hematology and Oncology, 2015, 13, 599-609.	0.3	26
120	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica, 2014, 99, 984-996.	3.5	124
121	Diagnosis and Risk Stratification in Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 791-813.	2.2	19
122	Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma. Haematologica, 2014, 99, 1846-1853.	3.5	17
123	Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance. Clinical Cancer Research, 2013, 19, 5591-5601.	7.0	48
124	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 2011, 37, 266-283.	7.7	66
125	Staphylococcus aureus pericardial abscess presenting as a localized bulge of the heart contour. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 818-819.	1.1	4
126	Acute and chronic renal artery stenosis. European Heart Journal, 2010, 31, 14-14.	2.2	1

#	Article	IF	Citations
127	New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway. Current Pharmaceutical Design, 2006, 12, 327-340.	1.9	31
128	A Novel In Vivo Animal Model for Human Multiple Myeloma Based on Bioluminescence Imaging of Tumor Cell Growth.. Blood, 2005, 106, 3452-3452.	1.4	2
129	Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clinical Cancer Research, 2005, 11, 429-39.	7.0	19
130	The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood, 2004, 103, 4362-4364.	1.4	171
131	A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.. Blood, 2004, 104, 3458-3458.	1.4	0
132	Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood, 2003, 102, 3354-3362.	1.4	114
133	Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clinical Cancer Research, 2003, 9, 5735-48.	7.0	39